Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

HIV-1-infected patients with advanced disease failing a raltegravir-containing salvage regimen in São Paulo, Brazil.

de Souza Cavalcanti J, de Paula Ferreira JL, Vidal JE, de Souza Guimarães PM, Moreira DH, de Macedo Brigido LF; São Paulo Salvage Workgroup.

Int J Antimicrob Agents. 2014 Mar;43(3):287-91. doi: 10.1016/j.ijantimicag.2013.10.020. Epub 2013 Nov 20.

PMID:
24359837
2.

In-vivo selection of the mutation F121Y in a patient failing raltegravir containing salvage regimen.

Souza Cavalcanti J, Minhoto Lança A, de Paula Ferreira JL, da Eira M, de Souza Dantas DS, de Macedo Brígido LF.

Antiviral Res. 2012 Jul;95(1):9-11. doi: 10.1016/j.antiviral.2012.04.007. Epub 2012 May 4.

3.

Monitoring the emergence of resistance mutations in patients infected with HIV-1 under salvage therapy with raltegravir in Rio de Janeiro, Brazil: a follow-up study.

Passaes CP, Guimarães ML, Cardoso SW, Pilotto JH, Veloso V, Grinsztejn B, Morgado MG.

J Med Virol. 2012 Dec;84(12):1869-75. doi: 10.1002/jmv.23409.

PMID:
23080489
4.

High frequency of dolutegravir resistance in patients failing a raltegravir-containing salvage regimen.

Cavalcanti Jde S, Ferreira JL, Guimarães PM, Vidal JE, Brigido LF.

J Antimicrob Chemother. 2015 Mar;70(3):926-9. doi: 10.1093/jac/dku439. Epub 2014 Nov 10.

5.

Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy.

Charpentier C, Karmochkine M, Laureillard D, Tisserand P, Bélec L, Weiss L, Si-Mohamed A, Piketty C.

HIV Med. 2008 Oct;9(9):765-70. doi: 10.1111/j.1468-1293.2008.00628.x. Epub 2008 Jul 21.

6.

Factors associated with virological success with raltegravir-containing regimens and prevalence of raltegravir-resistance-associated mutations at failure in the ARCA database.

Rusconi S, Vitiello P, Adorni F, Bruzzone B, De Luca A, Micheli V, Meraviglia P, Maserati R, Di Pietro M, Colao G, Penco G, Di Biagio A, Punzi G, Monno L, Zazzi M; Antiretroviral Resistance Cohort Analysis Collaborative Group.

Clin Microbiol Infect. 2013 Oct;19(10):936-42. doi: 10.1111/1469-0691.12100. Epub 2013 Jan 4.

7.

A cohort study of treatment-experienced HIV-1-infected patients treated with raltegravir: factors associated with virological response and mutations selected at failure.

Marcelin AG, Delaugerre C, Beaudoux C, Descamps D, Morand-Joubert L, Amiel C, Schneider V, Ferre V, Izopet J, Si-Mohamed A, Maillard A, Henquell C, Desbois D, Lazrek M, Signori-Schmuck A, Rogez S, Yerly S, Trabaud MA, Plantier JC, Fourati S, Houssaini A, Masquelier B, Calvez V, Flandre P; ANRS AC11 Resistance Group.

Int J Antimicrob Agents. 2013 Jul;42(1):42-7. doi: 10.1016/j.ijantimicag.2013.02.016. Epub 2013 Apr 4.

PMID:
23562640
8.

Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies.

Canducci F, Sampaolo M, Marinozzi MC, Boeri E, Spagnuolo V, Galli A, Castagna A, Lazzarin A, Clementi M, Gianotti N.

AIDS. 2009 Feb 20;23(4):455-60. doi: 10.1097/QAD.0b013e328323da60.

PMID:
19165083
9.

HIV-1 integrase resistance among antiretroviral treatment naive and experienced patients from Northwestern Poland.

Parczewski M, Bander D, Urbańska A, Boroń-Kaczmarska A.

BMC Infect Dis. 2012 Dec 21;12:368. doi: 10.1186/1471-2334-12-368.

10.

Study of genotypic and phenotypic HIV-1 dynamics of integrase mutations during raltegravir treatment: a refined analysis by ultra-deep 454 pyrosequencing.

Armenia D, Vandenbroucke I, Fabeni L, Van Marck H, Cento V, D'Arrigo R, Van Wesenbeeck L, Scopelliti F, Micheli V, Bruzzone B, Lo Caputo S, Aerssens J, Rizzardini G, Tozzi V, Narciso P, Antinori A, Stuyver L, Perno CF, Ceccherini-Silberstein F.

J Infect Dis. 2012 Feb 15;205(4):557-67. doi: 10.1093/infdis/jir821. Epub 2012 Jan 11.

11.

Long-lasting persistence of integrase resistance mutations in HIV-2-infected patients after raltegravir withdrawal.

Charpentier C, Larrouy L, Matheron S, Damond F, Delelis O, Mouscadet JF, Campa P, Chêne G, Brun-Vézinet F, Descamps D; French ANRS HIV-2 Cohort (ANRS CO 05).

Antivir Ther. 2011;16(6):937-40. doi: 10.3851/IMP1826.

PMID:
21900727
12.

Longitudinal analysis of integrase N155H variants in heavily treated patients failing raltegravir-based regimens.

Nguyen HL, Charpentier C, Nguyen N, de Truchis P, Molina JM, Ruxrungtham K, Delaugerre C.

HIV Med. 2013 Feb;14(2):85-91. doi: 10.1111/j.1468-1293.2012.01039.x. Epub 2012 Sep 20.

13.

G140S/Q148R and N155H mutations render HIV-2 Integrase resistant to raltegravir whereas Y143C does not.

Ni XJ, Delelis O, Charpentier C, Storto A, Collin G, Damond F, Descamps D, Mouscadet JF.

Retrovirology. 2011 Aug 19;8:68. doi: 10.1186/1742-4690-8-68.

14.

Raltegravir as functional monotherapy leads to virological failure and drug resistance in highly treatment-experienced HIV-infected patients.

Caby F, Valin N, Marcelin AG, Schneider L, Andrade R, Guiguet M, Tubiana R, Canestri A, Valantin MA, Peytavin G, Pacanowski J, Morand-Joubert L, Calvez V, Girard PM, Katlama C.

Scand J Infect Dis. 2010 Jul;42(6-7):527-32. doi: 10.3109/00365541003621502.

PMID:
20222846
15.

Analysis of transmitted resistance to raltegravir and selective pressure among HIV-1-infected patients on a failing HAART in Sao Paulo, Brazil.

Mantovani NP, Azevedo RG, Rabelato JT, Sanabani S, Diaz RS, Komninakis SV.

J Clin Microbiol. 2012 Jun;50(6):2122-5. doi: 10.1128/JCM.00539-12. Epub 2012 Mar 7.

16.

Four years data of raltegravir-based salvage therapy in HIV-1-infected, treatment-experienced patients: the SALIR-E Study.

Capetti A, Meraviglia P, Landonio S, Sterrantino G, Di Biagio A, Lo Caputo S, Ammassari A, Menzaghi B, De Socio GV, Franzetti M, Soria A, Meschiari M, Sasset L, Pellicanò G, Mazzotta E, Trezzi M, Celesia BM, Melzi S, Carenzi L, Ricci E, Rizzardini G.

Int J Antimicrob Agents. 2014 Feb;43(2):189-94. doi: 10.1016/j.ijantimicag.2013.10.013. Epub 2013 Nov 15.

PMID:
24315315
17.

Potent and sustained antiviral response of raltegravir-based highly active antiretroviral therapy in HIV type 1-infected children and adolescents.

Briz V, León-Leal JA, Palladino C, Moreno-Perez D, de Ory SJ, De José MI, González-Tomé MI, Martín CG, Pocheville I, Ramos JT, Leal M, Muñoz-Fernández MÁ.

Pediatr Infect Dis J. 2012 Mar;31(3):273-7. doi: 10.1097/INF.0b013e31824580e8.

PMID:
22330165
18.

Plasma raltegravir exposure influences the antiviral activity and selection of resistance mutations.

Garrido C, de Mendoza C, Alvarez E, García F, Morello J, Garcia S, Ribera E, Rodríguez-Novoa S, Gutierrez F, Soriano V; Sinres Team.

AIDS Res Hum Retroviruses. 2012 Feb;28(2):156-64. doi: 10.1089/AID.2010.0370. Epub 2011 May 6.

PMID:
21457126
19.

Early emergence of raltegravir resistance mutations in patients receiving HAART salvage regimens.

Baldanti F, Paolucci S, Gulminetti R, Brandolini M, Barbarini G, Maserati R.

J Med Virol. 2010 Jan;82(1):116-22. doi: 10.1002/jmv.21651.

PMID:
19950236
20.

Clinical experience of raltegravir with abacavir/lamivudine or zidovudine/lamivudine in HIV-infected Korean adults.

Kang SJ, An JH, Kim J, Jang MO, Kim SE, Park KH, Jung SI, Jang HC.

Jpn J Infect Dis. 2013;66(4):317-9.

Items per page

Supplemental Content

Write to the Help Desk